Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc.

INDVNYSE / NASDAQHealthcareMid cap

$36.28+$0.91 (+2.6%)

Last close · Data as of Nov 2, 2026

Market cap
$4.4B
P/E
21.1x
EV / EBITDA
15.1x
Revenue
$1.2B
Net margin
16.9%
ROCE
92.3%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Indivior Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 2 Nov 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change +$0.91 (+2.6%) from $35 to $36 · Last close Nov 2, 2026

Best weekday to invest, historically

The same weekly amount in INDV, bought on each weekday since 2021.

News & filings

What Indivior Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Return on capital employed of 92.3%.
  • Prices are as of 2 Nov 2026; price-based points are paused until newer prices arrive.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 2 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Read moreShow less

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Sector
Healthcare
Shares outstanding
125.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.4B
P/E
21.1x
P/B
-44.7x
EV / EBITDA
15.1x
EV / Sales
3.7x
P/S
3.6x
52-week high
$41.83
52-week low
$28.78

Profitability

Operating margin
21.4%
Net margin
16.9%
EBITDA margin
24.5%
ROE
-212.1%
ROCE
92.3%
ROA
17.5%
Asset turnover
1.03

Growth

Revenue
$1.2B
Revenue growth, 1Y
4.3%
Revenue CAGR, 3Y
11.2%
Net profit growth, 1Y
2900.0%
Free cash flow
-$94.0M

Solvency

Current ratio
0.71
Debt / Equity
-3.55
Debt / Assets
0.29
CFO / Net profit
-0.13
Cash / Market cap
4.4%

Where the revenue went

Of every $100 of FY2025 revenue, $17 was left as net income.

Indivior Pharmaceuticals, Inc. income statement flow, FY2025
Indivior Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$246.0M
RevenueGross profit$993.0M
Gross profitOperating expenses$728.0M
Gross profitOperating income$265.0M
Operating incomePretax income$239.0M
Operating incomeInterest and other expense$26.0M
Pretax incomeTax and other$29.0M
Pretax incomeNet income$210.0M

Revenue and net profit

Revenue grew 4.3% in FY2025; net profit is the dashed line.

Indivior Pharmaceuticals, Inc. revenue and net profit by fiscal year
Indivior Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$901.0M-$44.0M
FY2023$1.1B-$126.0M
FY2024$1.2B$7.0M
FY2025$1.2B$210.0M

Cash flows

FY2025: -$27.0M from operations, -$94.0M free after investment (dashed).

Indivior Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Indivior Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$4.0M-$9.0M
FY2023-$300.0M-$353.0M
FY2024$36.0M$5.0M
FY2025-$27.0M-$94.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.2B+4.3%1Y
EBITDA
$304.0M+241.6%1Y
Net profit
$210.0M+2,900.0%1Y
Cash from operations
-$27.0M-175.0%1Y
Free cash flow
-$94.0M-1,980.0%1Y
Revenue CAGR, 3Y
11.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.2B$304.0M$210.0M-$94.0M-212.1%+4.3%+2900.0%

Monthly returns

Month-by-month returns of INDV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.2B
Liabilities$1.3B
Equity-$99.0M
Paid-in capital$112.0M
Retained earnings-$243.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; INDV highlighted.

P/E against peers

INDV trades at 21.1x earnings against a peer median of 31.9x (a 34% discount).

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Indivior Pharmaceuticals, Inc.INDVthis companyP/E ↓ discount$4.4B21.1x-44.7x-212.1%15.1x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Amneal Pharmaceuticals, Inc.AMRX$4.3B59.9x-60.9x-101.8%11.1x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Peer median—31.9x3.0x6.6%15.1x

Year-to-date ROI

INDV since 1 January, against earlier years.

Historical volatility

INDV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Indivior Pharmaceuticals, Inc. operating margin by fiscal year
Indivior Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY202223.9%
FY202322.6%
FY202419.7%
FY202521.4%
LineFY2025
Cost of revenueCost Of Revenue$246.0M
Gross profitGross Profit$993.0M
Operating expensesOperating Expense$728.0M
Research and developmentResearch And Development$97.0M
Other operating expensesOther Operating Expenses-$3.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement—
Depreciation income statementDepreciation Income Statement—
Total expensesTotal Expenses$974.0M
Pretax incomePretax Income$239.0M

Learn while you research

Academy chapters picked for Indivior Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →